Drug intelligence / Profile preview

sacubitril allisartan amlodipine

Development stage: Preclinical
Lead developer: Shenzhen Salubris Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SAL0130 is Salubris's oral fixed-dose antihypertensive combination of sacubitril, allisartan, and amlodipine, submitted in China for treatment of primary hypertension. Sacubitril and allisartan form an angiotensin receptor-neprilysin inhibitor regimen: sacubitril-derived LBQ657 inhibits neprilysin to augment endogenous natriuretic peptides, while allisartan-derived EXP3174 blocks angiotensin II type 1 receptors. Amlodipine adds L-type calcium-channel blockade and vasodilation. Salubris states that the product is an ARNI plus calcium-channel blocker fixed-dose combination designed for multi-target blood-pressure reduction; its marketing application was accepted by China's NMPA in July 2026. ([salubris.com](https://www.salubris.com/NewsUpdates/info_itemid_5849.html))

Other names: Sacubitril Allisartan Amlodipine Tablets沙库巴曲阿利沙坦氨氯地平片

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)NEP (Neutral Endopeptidase)

Beyond the preview

Go deeper on sacubitril allisartan amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sacubitril allisartan amlodipine.